Skip to main content
. 2010 Jul 26;120(8):2858–2866. doi: 10.1172/JCI37539

Figure 5. Oncogenic KRAS mutations are associated with clinical resistance to everolimus.

Figure 5

Venn diagram representation of the distribution of molecular alterations in individual cancers. Response to everolimus according to the presence of genetic abnormalities within individual tumor samples is also shown.